1. Mean changes* in SCr and GFR by treatment group and baseline renal function
End point
Nesiritide
Placebo p
Peak SCr increase (mg/dL)
All available subjects
0.15 (n=133)
0.34 (n=133)
<0.001
Subjects with baseline SCr >1.2 mg/dL
0.02 (n=29)
0.48 (n=33)
0.001
Maximum decrease in GFR (mL/min/1.73 m2)
-10.8 (n=133)
-17.2 (n=133)
-0.2 (n=29)
-9.1 (n=33)
0.003
*Through discharge or hospital day 14, whichever came first
SCr=serum creatinine
GFR=glomerular filtration rate
Hebeler RF Jr, Oz MC. 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; May 9, 2006; Washington, DC. Poster 104, abstract 292.

2. Postoperative measures of renal function and urine output by treatment group
Parameter
Nesiritide
Placebo p
Urine output, 1st 24 hours (mL)
2926
2350
<0.001
Postoperative SCr increase >0.5 mg/dL (%) 7 23
Length of hospital stay (d)
9.1
11.4
0.043
SCr=serum creatinine
Hebeler RF Jr, Oz MC. 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; May 9, 2006; Washington, DC. Poster 104, abstract 292.